ClinicalTrials.gg
TerminatedNCT01467492Updated Aug 3, 2015Results posted

Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C

A Phase 4 interventional study of Telaprevir and Ribavirin in Hepatitis C, sponsored by Vertex Pharmaceuticals Incorporated. Terminated at 27 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-08-03.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 4, Interventional, and Treatment

Why this study was terminated
It was decided by Sponsor on 13 January 2014 to terminate study early at primary efficacy endpoint as part of a decision to modify drug development plan.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
121
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing telaprevir in Hepatitis C — none open to participants now, none under way, none of them phase 3. telaprevir · Hepatitis C.

Enrollment
11th of 39
121 · median 30
Started
2012
with 11 others
Phase 4
5 of 39
none open now
Registered
21st of 39
by date
Lead sponsor
12 of 39
Vertex Pharmaceuticals Incorporated

Among the 39 studies testing telaprevir in Hepatitis C, this one is the 11th largest by enrollment, is one of 12 that started in 2012, is one of 5 in phase 4, and was the 21st registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 39 studies testing telaprevir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About telaprevir

telaprevir: first FDA approval 2011 (INCIVEK), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing telaprevir in Hepatitis C as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) in treatment-experienced Black/African American and non-Black/African American participants with Genotype 1 Chronic Hepatitis C (CHC), who have not achieved a sustained viral response with a prior course of interferon-based therapy.

Read the detailed description

This is a single-arm, open-label, multicenter study of treatment-experienced participants with Genotype 1 CHC, who self-identified as Black/African American (Group A) or who did not self-identify as Black/African American (Group B). Participants did not achieve a sustained virologic response 24 weeks after at least 1 prior course of Peg-IFN-alfa-2a/RBV therapy of standard duration, and have 1 of the following viral responses:

  • Prior relapse: Participant had a documented undetectable hepatitis C virus ribonucleic acid (HCV RNA) level at the planned end of treatment of at least 42 weeks duration (HCV RNA evaluated anytime between 3 weeks before and 6 weeks after the last dose of Peg IFN-alfa-2a or RBV).
  • Prior null response: Participant had a \<2-log10 decrease in HCV RNA at 12 weeks, during prior Peg IFN-alfa-2a/RBV treatment, but never achieved undetectable HCV RNA while on treatment.
  • Prior partial response: Participant had a >=2-log10 decrease in HCV RNA at 12 weeks, during prior Peg IFN-alfa-2a/RBV treatment, but never achieved undetectable HCV RNA while on treatment.
03

Conditions studied

  • Hepatitis C

Browse trials for

Keywords

  • VX-950, Incivek
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants self-identify as Black/African American (Group A) or did not self-identify as Black/African American (Group B)
  • Participants have Genotype 1 CHC and laboratory evidence of virus (HCV) infection for at least 6 months
  • Participants did not achieve sustained viral response 24 weeks after last dose of study drug (SVR24), after at least 1 prior course of Peg-IFN-alfa-2a/RBV therapy of standard duration

Exclusion criteria

Exclusion Criteria:

  • Participants have received previous treatment with telaprevir or any other protease inhibitor(s) for CHC
  • Participants who have evidence of hepatic decompensation
  • Participants have diagnosed or suspected hepatocellular carcinoma
  • Participants have any other cause of significant liver disease in addition to
  • Participants are currently abusing illicit drugs or alcohol, or have history of illicit substance or alcohol abuse within 2 years before the screening visit
  • Participants who participated in any drug study within 90 days before dosing
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    Black

    Telaprevir 750 milligram (mg) tablet 3 times per day for 12 weeks in combination with Peg-IFN-alfa-2a 180 microgram per week (mcg/week) subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 milligram per day (mg/day) (for participants weighing \<75 kilograms \[kg\]) or 1200 mg/day (for participants weighing \>=75 kg) for 24 or 48 weeks.

    Drug: Telaprevir · Drug: Ribavirin · Biological: Pegylated Interferon Alfa-2a

  • Experimental
    Non-Black

    Telaprevir 750 mg tablet 3 times per day for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day (for participants weighing \<75 kg) or 1200 mg/day (for participants weighing \>=75 kg) for 24 or 48 weeks.

    Drug: Telaprevir · Drug: Ribavirin · Biological: Pegylated Interferon Alfa-2a

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Viral Response 12 Weeks After Last Actual Dose of Study Drug (SVR12)

    SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (\<lower limit of quantification) at 12 weeks after last actual dose of study drug. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL).

    Time frame: 12 weeks after last actual dose of study drug (up to Week 60)

Secondary outcomes

  1. Percentage of Participants With Sustained Viral Response 24 Weeks After Last Actual Dose of Study Drug (SVR24)

    SVR24 was defined as an undetectable HCV RNA Levels (\<lower limit of quantification) at 24 weeks after last actual dose of study drug. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL.

    Time frame: 24 weeks after last actual dose of study drug (up to Week 72)

  2. Percentage of Participants With Extended Rapid Viral Response (eRVR)

    The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. eRVR was defined as undetectable HCV RNA (\<lower limit of quantification) at both 4 weeks and 12 weeks after the start of study treatment.

    Time frame: Week 4 and Week 12

  3. Percentage of Participants With Relapse

    The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. Relapse was defined as having undetectable HCV RNA (\<lower limit of quantification) at actual end of treatment (EOT) and followed by detectable HCV RNA (\>=lower limit of quantification) during follow-up.

    Time frame: 4 weeks (Wk) (up to Week 52), 12 weeks (up to Week 60) and 24 weeks (up to Week 72) after actual EOT

  4. Percentage of Participants With Virologic Breakthrough

    The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. Virologic breakthrough on treatment was defined as an increase of at least 1 log10 from nadir or confirmed detectable HCV RNA (\>=lower limit of quantification) after undetectable HCV RNA (\<lower limit of quantification). Percentages are calculated by using total number in FA set as denominator, in each category.

    Time frame: Week 2, 4, 8, and 12

  5. Percentage of Participants With On Treatment Virologic Failure

    On treatment virologic failure was defined as meeting any futility rule or completing assigned treatment duration and having detectable HCV RNA at EOT. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. Futility rules: 1) Virologic breakthrough (at least 1 log10 increase from nadir or confirmed detectable HCV RNA after undetectable HCV RNA) from Day 1 through Week 24 or 48 (depending on treatment duration); 2) HCV RNA \>1000 IU/mL during Weeks 4 to 12, inclusive; 3) Detectable HCV RNA after Week 12. Percentages are calculated by using total number in FA set as denominator, in each category.

    Time frame: Week 2, 4, 8, 12, 16, 24, 28, 36, 40, and 48

  6. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes SAE as well as Non-SAEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event.

    Time frame: Up to Week 52

  7. Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region

    Sequence analysis of the HCV NS3-4A region was performed to monitor telaprevir-resistant variants. HCV RNA was isolated from the plasma, amplified by reverse transcription-polymerase chain reaction (RT-PCR), and sequenced (sequencing assay limit of detection HCV RNA \>=1000 IU/mL). Results of this outcome measure were to be reported for overall participants instead of by race and by prior response.

    Time frame: up to Week 72

Other outcomes

  1. Plasma Concentration of Telaprevir, Peginterferon Alfa-2a (Peg-IFN) and Ribavirin (RBV)

    Time frame: 48 weeks

07

Results

Posted Jun 16, 2015
Limitations and caveats
It was decided by Sponsor on 13 January 2014 to terminate the study early as part of a decision to modify the drug development plan. Eligible participants completed virologic follow-up after termination.

Participant flow

Study included Prior Relapser (prior HCV treatment with pegylated interferon alfa/ribavirin \[Peg-IFN/RBV\] and experienced viral relapse) and Prior Null/Partial Responder (prior HCV treatment with Peg-IFN/RBV and had null/partial response) participants.

Participant flow — Overall Study
MilestoneGroup A - BlackGroup B - Non-Black
Started8338
Completed6125
Not completed2213
Withdrew: Withdrawal by subject64
Withdrew: Study terminated by sponsor64
Withdrew: Adverse event43
Withdrew: Lost to follow-up32
Withdrew: Undefined20
Withdrew: Enrolled but not treated10

Outcome measures

PrimaryPercentage of Participants With Sustained Viral Response 12 Weeks After Last Actual Dose of Study Drug (SVR12)

SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (\<lower limit of quantification) at 12 weeks after last actual dose of study drug. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL).

Time frame:
12 weeks after last actual dose of study drug (up to Week 60)
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Viral Response 12 Weeks After Last Actual Dose of Study Drug (SVR12)
percentage of participantsGroup A - BlackGroup B - Non-Black
Prior Null Response (n = 41, 10)26.820.0
Prior Partial Response (n= 20, 6)40.033.3
Prior Relapse ( n= 21, 22)66.759.1
Total (n= 82, 38)40.244.7
SecondaryPercentage of Participants With Sustained Viral Response 24 Weeks After Last Actual Dose of Study Drug (SVR24)

SVR24 was defined as an undetectable HCV RNA Levels (\<lower limit of quantification) at 24 weeks after last actual dose of study drug. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL.

Time frame:
24 weeks after last actual dose of study drug (up to Week 72)
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Viral Response 24 Weeks After Last Actual Dose of Study Drug (SVR24)
percentage of participantsGroup A - BlackGroup B - Non-Black
Prior Null Response (n = 41, 10)19.520.0
Prior Partial Response (n= 20, 6)30.016.7
Prior Relapse ( n= 21, 22)61.950.0
Total (n= 82, 38)32.936.8
SecondaryPercentage of Participants With Extended Rapid Viral Response (eRVR)

The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. eRVR was defined as undetectable HCV RNA (\<lower limit of quantification) at both 4 weeks and 12 weeks after the start of study treatment.

Time frame:
Week 4 and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Extended Rapid Viral Response (eRVR)
percentage of participantsGroup A - BlackGroup B - Non-Black
Prior Null Response (n = 41, 10)24.430.0
Prior Partial Response (n= 20, 6)45.066.7
Prior Relapse ( n= 21, 22)66.768.2
Total (n= 82, 38)40.257.9
SecondaryPercentage of Participants With Relapse

The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. Relapse was defined as having undetectable HCV RNA (\<lower limit of quantification) at actual end of treatment (EOT) and followed by detectable HCV RNA (\>=lower limit of quantification) during follow-up.

Time frame:
4 weeks (Wk) (up to Week 52), 12 weeks (up to Week 60) and 24 weeks (up to Week 72) after actual EOT
Reported as:
Number · percentage of participants
Percentage of Participants With Relapse
percentage of participantsGroup A - BlackGroup B - Non-Black
Prior Null Response, 4 Wk After EOT (n=17,3)23.533.3
Prior Null Response, 12 Wk After EOT (n=17,3)23.533.3
Prior Null Response, 24 Wk After EOT (n=17,3)29.433.3
Prior Partial Response, 4Wk After EOT (n=13,4)15.450.0
Prior Partial Response, 12 Wk After EOT (n=13,4)23.150.0
Prior Partial Response, 24 Wk After EOT (n=13,4)23.150.0
Prior Relapse, 4 Wk After EOT (n=18,19)11.115.8
Prior Relapse, 12 Wk After EOT (n=18,19)11.126.3
Prior Relapse, 24 Wk After EOT (n=18,19)11.126.3
Total, 4 Wk After EOT (n=48,26)16.723.1
Total, 12 Wk After EOT (n=48,26)18.830.8
Total, 24 Wk After EOT (n=48,26)20.830.8
SecondaryPercentage of Participants With Virologic Breakthrough

The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. Virologic breakthrough on treatment was defined as an increase of at least 1 log10 from nadir or confirmed detectable HCV RNA (\>=lower limit of quantification) after undetectable HCV RNA (\<lower limit of quantification). Percentages are calculated by using total number in FA set as denominator, in each category.

Time frame:
Week 2, 4, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Breakthrough
percentage of participantsGroup A - BlackGroup B - Non-Black
Prior Null Response, Week 200
Prior Null Response, Week 41.22.6
Prior Null Response, Week 83.75.3
Prior Null Response, Week 126.15.3
Prior Partial Response, Week 200
Prior Partial Response, Week 42.40
Prior Partial Response, Week 82.40
Prior Partial Response, Week 122.40
Prior Relapse, Week 200
Prior Relapse, Week 400
Prior Relapse, Week 800
Prior Relapse, Week 121.20
Total, Week 200
Total, Week 43.72.6
Total, Week 83.75.3
Total, Week 129.85.3
SecondaryPercentage of Participants With On Treatment Virologic Failure

On treatment virologic failure was defined as meeting any futility rule or completing assigned treatment duration and having detectable HCV RNA at EOT. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. Futility rules: 1) Virologic breakthrough (at least 1 log10 increase from nadir or confirmed detectable HCV RNA after undetectable HCV RNA) from Day 1 through Week 24 or 48 (depending on treatment duration); 2) HCV RNA \>1000 IU/mL during Weeks 4 to 12, inclusive; 3) Detectable HCV RNA after Week 12. Percentages are calculated by using total number in FA set as denominator, in each category.

Time frame:
Week 2, 4, 8, 12, 16, 24, 28, 36, 40, and 48
Reported as:
Number · percentage of participants
Percentage of Participants With On Treatment Virologic Failure
percentage of participantsGroup A - BlackGroup B - Non-Black
Prior Null Response, Week 200
Prior Null Response, Week 44.92.6
Prior Null Response, Week 88.57.9
Prior Null Response, Week 1212.27.9
Prior Null Response, Week 1619.57.9
Prior Null Response, Week 2423.210.5
Prior Null Response, Week 2823.213.2
Prior Null Response, Week 3625.613.2
Prior Null Response, Week 4028.013.2
Prior Null Response, Week 4829.313.2
Prior Partial Response, Week 200
Prior Partial Response, Week 42.40
Prior Partial Response, Week 82.40
Prior Partial Response, Week 124.90
Prior Partial Response, Week 164.92.6
Prior Partial Response, Week 246.17.9
Prior Partial Response, Week 286.110.5
Prior Partial Response, Week 367.310.5
Prior Partial Response, Week 407.310.5
Prior Partial Response, Week 487.310.5
Prior Relapse, Week 200
Prior Relapse, Week 400
Prior Relapse, Week 800
Prior Relapse, Week 121.20
Prior Relapse, Week 161.20
Prior Relapse, Week 241.22.6
Prior Relapse, Week 281.22.6
Prior Relapse, Week 361.22.6
Prior Relapse, Week 401.25.3
Prior Relapse, Week 481.25.3
Total, Week 200
Total, Week 47.32.6
Total, Week 811.07.9
Total, Week 1218.37.9
Total, Week 1625.610.5
Total, Week 2430.521.1
Total, Week 2830.526.3
Total, Week 3634.126.3
Total, Week 4036.628.9
Total, Week 4837.828.9
SecondaryPercentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes SAE as well as Non-SAEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event.

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
percentage of participantsGroup A - BlackGroup B - Non-Black
AE96.3100.0
SAE8.515.8
SecondaryNumber of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region

Sequence analysis of the HCV NS3-4A region was performed to monitor telaprevir-resistant variants. HCV RNA was isolated from the plasma, amplified by reverse transcription-polymerase chain reaction (RT-PCR), and sequenced (sequencing assay limit of detection HCV RNA \>=1000 IU/mL). Results of this outcome measure were to be reported for overall participants instead of by race and by prior response.

Time frame:
up to Week 72
Reported as:
Number · participants
Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region
participantsAll Participants
Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region47
Other pre-specifiedPlasma Concentration of Telaprevir, Peginterferon Alfa-2a (Peg-IFN) and Ribavirin (RBV)
Time frame:
48 weeks

No measurements were reported for this outcome.

Adverse events

Collected over Up to Week 52. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A - Black—7/82 (8.5%)79/82 (96.3%)
Group B - Non-Black—6/38 (15.8%)38/38 (100%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventGroup A - BlackGroup B - Non-Black
AnaemiaBlood and lymphatic system disorders0/822/38
PancreatitisGastrointestinal disorders0/821/38
DehydrationMetabolism and nutrition disorders1/821/38
HypotensionVascular disorders0/821/38
Angina pectorisCardiac disorders0/821/38
Facial bones fractureInjury, poisoning and procedural complications0/821/38
Hand fractureInjury, poisoning and procedural complications0/821/38
LacerationInjury, poisoning and procedural complications0/821/38
Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/821/38
InsomniaPsychiatric disorders0/821/38
Most frequent other events
Showing 10 of 234
Most frequent other events
EventGroup A - BlackGroup B - Non-Black
FatigueGeneral disorders31/8226/38
AnaemiaBlood and lymphatic system disorders40/8219/38
NauseaGastrointestinal disorders20/8217/38
PruritusSkin and subcutaneous tissue disorders33/8216/38
RashSkin and subcutaneous tissue disorders15/8213/38
HeadacheNervous system disorders14/8213/38
InsomniaPsychiatric disorders8/8210/38
DizzinessNervous system disorders7/828/38
Anal pruritusGastrointestinal disorders16/825/38
Influenza like illnessGeneral disorders15/827/38

Baseline characteristics

Full Analysis (FA) Set included all enrolled participants who received at least 1 dose of any study drug.

Age, Continuous
Age, Continuous(years)Group A - BlackGroup B - Non-BlackTotal
Mean57.7 ± 5.5955.8 ± 5.9557.1 ± 5.76
Sex: Female, Male
Sex: Female, Male(Participants)Group A - BlackGroup B - Non-BlackTotal
Female34640
Male483280
08

Study locations

27 sites
  • Alabama
    Birmingham, Alabama, United States
  • California
    San Francisco, California, United States
  • Connecticut
    New Haven, Connecticut, United States
  • Washington, DC
    Washington, District of Columbia, United States
  • Florida
    Miami, Florida, United States
  • Florida
    Orlando, Florida, United States
  • Florida
    Tampa, Florida, United States
  • Florida
    West Palm Beach, Florida, United States
  • Georgia
    Atlanta, Georgia, United States
  • Illinois
    Chicago, Illinois, United States
  • Louisiana
    Baton Rouge, Louisiana, United States
  • Louisiana
    New Orleans, Louisiana, United States
  • Louisiana
    Shreveport, Louisiana, United States
  • Maryland
    Baltimore, Maryland, United States
  • Massachusetts
    Boston, Massachusetts, United States
  • Michigan
    Detroit, Michigan, United States
  • New Jersey
    Vineland, New Jersey, United States
  • New York
    Bronx, New York, United States
  • New York
    New York, New York, United States
  • North Carolina
    Charlotte, North Carolina, United States
  • North Carolina
    Durham, North Carolina, United States
  • Pennsylvania
    Philadelphia, Pennsylvania, United States
  • Texas
    Dallas, Texas, United States
  • Texas
    Houston, Texas, United States
  • Texas
    San Antoinio, Texas, United States
  • Virginia
    Norfolk, Virginia, United States
  • Washington
    Seattle, Washington, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2011
First posted
Nov 8, 2011
Start
Jan 2012
Primary completionActual
May 2014
CompletionActual
May 2014
Results first posted
Jun 16, 2015
Last update
Aug 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01467492
Responsible party
Sponsor
First posted
Nov 8, 2011
Start date
Jan 2012
Primary completion
May 2014
Completion
May 2014
Results posted
Jun 16, 2015
Last update
Aug 3, 2015

Study contacts

Medical Monitor
study director · Vertex Pharmaceuticals Incorporated

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telaprevir · Ribavirin · Peginterferon alfa-2a

Start the discussion